Patents by Inventor Ellen Garber

Ellen Garber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140079697
    Abstract: The invention provides humanized antibodies that bind to a plurality of b-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides therapeutic reagents and methods of treating disorders associated with detrimental MCP activity.
    Type: Application
    Filed: July 2, 2013
    Publication date: March 20, 2014
    Applicant: Biogen Idec MA Inc.
    Inventors: Antonin R. DE FOUGEROLLES, Victor E. KOTELIANSKI, Ellen GARBER, Carl REID, Jose W. SALDANHA, Herman VAN VLIJMEN
  • Patent number: 8669345
    Abstract: Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are Nogo receptor antagonist polynucleotides. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, nucleic acids encoding the same and antagonist polynucleotides.
    Type: Grant
    Filed: January 26, 2007
    Date of Patent: March 11, 2014
    Assignee: Biogen Idec MA Inc.
    Inventors: Daniel H. S. Lee, Dingyi Wen, R. Blake Pepinsky, Jane K. Relton, Xinzhong Wang, Alexey Lugovskoy, Werner Meier, Ellen A. Garber, Laura Silvian, Paul H. Weinreb
  • Patent number: 8618252
    Abstract: The compositions and methods of the present invention are based, in part, on our discovery that an effector function mediated by an Fc-containing polypeptide can be altered by modifying one or more amino acid residues within the polypeptide (by, for example, electrostatic optimization). The polypeptides that can be generated according to the methods of the invention are highly variable, and they can include antibodies and fusion proteins that contain an Fc region or a biologically active portion thereof.
    Type: Grant
    Filed: December 13, 2010
    Date of Patent: December 31, 2013
    Assignee: Biogen Idec MA Inc.
    Inventors: Graham K. Farrington, Alexey Alexandrovich Lugovskoy, Werner Meier, John K. Eldredge, Ellen Garber
  • Patent number: 8609407
    Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.
    Type: Grant
    Filed: January 23, 2012
    Date of Patent: December 17, 2013
    Assignee: Biogen Idec MA Inc.
    Inventors: Sha Mi, R. Blake Pepinsky, Zhaohui Shao, Ellen A. Garber, Steven D. Miklasz, Christilyn Graff
  • Publication number: 20130287796
    Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.
    Type: Application
    Filed: March 14, 2013
    Publication date: October 31, 2013
    Inventors: Sha MI, R. Blake Pepinsky, Zhaohui Shao, Ellen A. Garber, Steven D. Miklasz, Christilyn Graff
  • Patent number: 8519112
    Abstract: The invention provides humanized antibodies that bind to a plurality of ?-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides therapeutic reagents and methods of treating disorders associated with detrimental MCP activity.
    Type: Grant
    Filed: February 14, 2011
    Date of Patent: August 27, 2013
    Assignee: Biogen Idec MA Inc.
    Inventors: Antonin R. De Fougerolles, Victor E. Kotelianski, Ellen Garber, Carl Reid, Jose W. Saldanha, Herman Van Vlijmen
  • Patent number: 8431125
    Abstract: The invention provides antibodies that bind to a plurality of ?-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides cells producing the antibodies, and methods of making and using the same.
    Type: Grant
    Filed: June 9, 2011
    Date of Patent: April 30, 2013
    Assignee: Biogen Idec MA, Inc.
    Inventors: Antonin R. De Fougerolles, Victor E. Kotelianski, Carl Reid, Ellen Garber
  • Patent number: 8410061
    Abstract: Variants of hedgehog protein that contain N-terminal modifications are described that can block hedgehog function; thus allowing these variants to serve as functional antagonists. These peptides have a primary amino acid sequence lacking the ability to elicit a hedgehog-dependent response in C3H 10T1/2 cells but having the ability to bind to the hedgehog receptor, patched-1. Methods for producing such functional antagonists and methods of using the functional antagonists are also described.
    Type: Grant
    Filed: June 5, 2002
    Date of Patent: April 2, 2013
    Assignee: Curis. Inc.
    Inventors: Kevin Williams, Paul Rayhorn, Ellen A. Garber, R. Blake Pepinsky
  • Patent number: 8318917
    Abstract: The invention provides a method of producing aglycosylated Fc-containing polypeptides, such as antibodies, having desired effector function. The invention also provides aglycosylated antibodies produced according to the method as well as methods of using such antibodies as therapeutics.
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: November 27, 2012
    Assignee: Biogen Idec MA Inc.
    Inventors: Frederick R. Taylor, Ellen Garber
  • Patent number: 8293237
    Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: October 23, 2012
    Assignees: UCB Pharma, S.A., Biogen Idec MA Inc.
    Inventors: Linda C. Burkly, Janine L. Ferrant-Orgettas, Ellen A. Garber, Yen-Ming Hsu, Lihe Su, Frederick R. Taylor, Ralph Adams, Derek Thomas Brown, Andrew George Popplewell, Martyn Kim Robinson, Anthony Shock, Kerry Louise Tyson
  • Publication number: 20120190070
    Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.
    Type: Application
    Filed: January 23, 2012
    Publication date: July 26, 2012
    Inventors: Sha MI, R. Blake Pepinsky, Zhaohui Shao, Ellen A. Garber, Steven D. Miklasz, Christilyn Graff
  • Publication number: 20120177638
    Abstract: Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures.
    Type: Application
    Filed: November 15, 2011
    Publication date: July 12, 2012
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Michael Karpusas, Paul D. Lyne, Jose William Saldanha, Ellen A. Garber
  • Publication number: 20120100140
    Abstract: A method of producing Fc-containing polypeptides, such as antibodies, having stabilized Fc regions is provided, together with stabilized Fc polypeptides produced according to these methods as well as methods of using such antibodies as therapeutics.
    Type: Application
    Filed: January 22, 2010
    Publication date: April 26, 2012
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Christopher L. Reyes, Eric Chan, Frederick R. Taylor, Ellen Garber, Brian Robert Miller, Stephen Demarest, Scott Glaser
  • Publication number: 20120100575
    Abstract: The invention provides a method of producing aglycosylated Fc-containing polypeptides, such as antibodies, having desired effector function. The invention also provides aglycosylated antibodies produced according to the method as well as methods of using such antibodies as therapeutics.
    Type: Application
    Filed: December 21, 2010
    Publication date: April 26, 2012
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Frederick R. TAYLOR, Ellen GARBER
  • Patent number: 8147829
    Abstract: The invention relates to antibodies which bind to insulin like growth factor receptor-1 (IGF-1R) and uses thereof, in particular in the diagnosis and treatment of cancer. Specific human and murine monoclonal antibodies which inhibit IGF-1R-mediated pro-survival and tumor proliferation pathways, and variants, fragments, and derivatives thereof are provided. Also provided are specific human and murine monoclonal antibodies which block the ability of the ligands, insulin like growth factor 1 (IGF-1) and insulin like growth factor 2 (IGF-2) to bind to IGF-1R, as well as fragments, variants and derivatives of such antibodies. The invention also includes polynucleotides encoding the above antibodies or fragments, variants or derivatives thereof, as well as vectors and host cells comprising such polynucleotides. The invention further includes methods of diagnosing and treating cancer using antibodies of the invention.
    Type: Grant
    Filed: September 14, 2009
    Date of Patent: April 3, 2012
    Assignee: Biogen Idec MA Inc.
    Inventors: Kandasamy Hariharan, Scott Glaser, Ellen Garber, Christilyn Graff, Christopher L. Reyes, Stephen Demarest
  • Patent number: 8128926
    Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.
    Type: Grant
    Filed: March 24, 2009
    Date of Patent: March 6, 2012
    Assignee: Biogen Idec MA Inc.
    Inventors: Sha Mi, R. Blake Pepinsky, Zhaohui Shao, Ellen A. Garber, Steven D. Miklasz, Christilyn Graff
  • Publication number: 20120039873
    Abstract: The invention provides antibodies that bind to a plurality of ?-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides cells producing the antibodies, and methods of making and using the same.
    Type: Application
    Filed: June 9, 2011
    Publication date: February 16, 2012
    Inventors: Antonin R. De Fougerolles, Victor E. Kotelianski, Carl Reid, Ellen Garber
  • Publication number: 20120009178
    Abstract: Anti-Tweak antibodies are described.
    Type: Application
    Filed: September 9, 2011
    Publication date: January 12, 2012
    Inventors: Linda C. Burkly, Ellen Garber, Alexey Lugovskoy
  • Publication number: 20120003210
    Abstract: The compositions and methods of the present invention are based, in part, on our discovery that an effector function mediated by an Fc-containing polypeptide can be altered by modifying one or more amino acid residues within the polypeptide (by, for example, electrostatic optimization). The polypeptides that can be generated according to the methods of the invention are highly variable, and they can include antibodies and fusion proteins that contain an Fc region or a biologically active portion thereof.
    Type: Application
    Filed: December 13, 2010
    Publication date: January 5, 2012
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Graham K. FARRINGTON, Alexey Alexandrovich LUGOVSKOY, Werner MEIER, John K. ELDREDGE, Ellen GARBER
  • Publication number: 20120003235
    Abstract: The instant invention is based, at least in part on the identification of a new class of antibodies that result, e.g., in improved LT blocking capabilities. Methods of making the subject binding molecules and methods of using the binding molecules of the invention to antagonize LT?R signaling are also provided.
    Type: Application
    Filed: December 31, 2009
    Publication date: January 5, 2012
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Ann M. Ranger, Ellen Garber, Justin A. Caravella, Alexey A. Lugovskoy, Joseph Arndt, Frederick R. Taylor, Giovanna Antognetti, Eric Day